Uptake Inhibitors but not Substrates Induce Protease Resistance in Extracellular Loop Two of the Dopamine Transporter
Open Access
- 1 March 2004
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 65 (3) , 692-701
- https://doi.org/10.1124/mol.65.3.692
Abstract
Changes in protease sensitivity of extracellular loop two (EL2) of the dopamine transporter (DAT) during inhibitor and substrate binding were examined using trypsin proteolysis and epitope-specific immunoblotting. In control rat striatal membranes, proteolysis of DAT in a restricted region of EL2 was produced by 0.001 to 10 μg/ml trypsin. However, in the presence of the dopamine uptake blockers [2-(diphenylmethoxyl) ethyl]-4-(3phenylpropyl) piperazine (GBR 12909), mazindol, 2β-carbomethoxy-3β-(4-flourophenyl)tropane (β-CFT), nomifensine, benztropine, or (-)-cocaine, 100- to 1000-fold higher concentrations of trypsin were required to produce comparable levels of proteolysis. Protease resistance induced by ligands was correlated with their affinity for DAT binding, was not observed with Zn2+, (+)-cocaine, or inhibitors of norepinephrine or serotonin transporters, and was not caused by altered catalytic activity of trypsin. Together, these results support the hypothesis that the interaction of uptake inhibitors with DAT induces a protease-resistant conformation in EL2. In contrast, binding of substrates did not induce protease resistance in EL2, suggesting that substrates and inhibitors interact with DAT differently during binding. To assess the effects of EL2 proteolysis on DAT function, the binding and transport properties of trypsin-digested DAT were assayed with [3H]CFT and [3H]dopamine. Digestion decreased the Bmax for binding and the Vmax for uptake in amounts that were proportional to the extent of proteolysis, indicating that the structural integrity of EL2 is required for maintenance of both DAT binding and transport functions. Together this data provides novel information about inhibitor and substrate interactions at EL2, possibly relating the protease resistant DAT conformation to a mechanism of transport inhibition.Keywords
This publication has 42 references indexed in Scilit:
- Interactions of Tryptamine Derivatives with Serotonin Transporter Species Variants Implicate Transmembrane Domain I in Substrate RecognitionMolecular Pharmacology, 2001
- The N-terminal region of the plasma membrane Ca2+ pump does not separate from the main catalytic fragments after proteolysisBiochimica et Biophysica Acta (BBA) - Biomembranes, 2000
- Transport-dependent Accessibility of a Cytoplasmic Loop Cysteine in the Human Dopamine TransporterPublished by Elsevier ,2000
- Transmembrane Domain I Contributes to the Permeation Pathway for Serotonin and Ions in the Serotonin TransporterJournal of Neuroscience, 1999
- High Affinity Recognition of Serotonin Transporter Antagonists Defined by Species-scanning MutagenesisJournal of Biological Chemistry, 1998
- The Third Transmembrane Domain of the Serotonin Transporter Contains Residues Associated with Substrate and Cocaine BindingPublished by Elsevier ,1997
- Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium.Proceedings of the National Academy of Sciences, 1994
- In vivo expression of the lacY gene in two segments leads to functional lac permease.Proceedings of the National Academy of Sciences, 1990
- Comparative measurements of membrane potentials with microelectrodes and voltage-sensitive dyesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1984
- Membrane potentials in pinched‐off presynaptic nerve ternimals monitored with a fluorescent probe: evidence that synaptosomes have potassium diffusion potentials.The Journal of Physiology, 1975